AIDX

20/20 Biolabs Inc. (AIDX) Economic Moat Analysis (2026)

Invetso Score: 2.4/10 — Weak · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Intangible Assets

Score: 2.4 (Weak)

AIDX has no provided evidence of durable brand, patent, or regulatory protection that would let it sustain pricing power versus peers.

Negative TTM ROIC and ROCE indicate the company is not currently converting any intangible advantage into superior returns relative to capital employed.

With no disclosed long-run margin history in the supplied data, there is no peer-visible proof of proprietary assets translating into persistent margin resilience.

Switching Costs

Score:

The supplied metrics do not show retention-linked economics, so there is no evidence that customers face meaningful switching friction versus alternative providers.

Negative ROIC alongside low asset turnover suggests the business is not yet monetizing a sticky installed base better than peers.

Absent filing-based evidence of workflow integration, contractual lock-in, or mission-critical dependence, switching costs appear limited and replicable.

Network Effects

Score:

No provided data indicates a user, data, or ecosystem flywheel that would make the platform more valuable as adoption rises versus peers.

Negative profitability metrics argue against a self-reinforcing scale loop that is already producing superior unit economics.

Without evidence of peer-dependent participation or ecosystem control, network effects cannot be credited as a durable moat driver.

Cost Advantage

Score:

TTM ROIC and ROCE below zero imply AIDX is not demonstrating a structural cost edge that would support better margins than peers.

Asset turnover of 0.33 suggests weak capital productivity, which is inconsistent with a durable operating-cost advantage.

No supplied evidence shows lower input costs, scale purchasing power, or process efficiency that would be hard for peers to replicate.

Efficient Scale

Score:

The available metrics do not show that AIDX operates in a niche where one or two players can serve demand efficiently enough to deter entry.

Negative returns on capital suggest the company is not yet capturing the economics of a protected scale position versus peers.

No filing-based evidence indicates regulated capacity limits, exclusive access, or market structure that would make the business hard to contest.

Overall Score

Score:

AIDX shows no supplied evidence of durable moat strength versus peers, and the negative ROIC/ROCE profile suggests any competitive advantages are not yet translating into persistent pricing power, retention, or superior capital returns.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on 20/20 Biolabs Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →